Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Thursday, December 31, 2020.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2020 (2020-12-31): -388.31%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-257.58%
RETURN ON EQUITY (ROE) AVG 3Y
-197.65%
RETURN ON EQUITY (ROE) AVG 5Y
-111.06%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Karyopharm Therapeutics Inc.
Market Cap
$15.54M
Return on Equity (ROE)
N/A
TTM Avg
-257.58%
3Y Avg
-197.65%
5Y Avg
-111.06%
Market Cap
$15.65M
Return on Equity (ROE)
-348.81%
TTM Avg
-160.92%
3Y Avg
-184.71%
5Y Avg
-151.29%
Market Cap
$15.10M
Return on Equity (ROE)
4.02%
TTM Avg
8.39%
3Y Avg
11.64%
5Y Avg
14.29%
Market Cap
$15.24M
Return on Equity (ROE)
-951.92%
TTM Avg
-161.65%
3Y Avg
-122.41%
5Y Avg
-87.71%
Market Cap
$15.79M
Return on Equity (ROE)
-271.81%
TTM Avg
-934.34%
3Y Avg
-347.56%
5Y Avg
-265.02%
Market Cap
$15.03M
Return on Equity (ROE)
-42.72%
TTM Avg
-65.53%
3Y Avg
-58.02%
5Y Avg
-43.63%
Market Cap
$16.50M
Return on Equity (ROE)
N/A
TTM Avg
-416.37%
3Y Avg
-259.03%
5Y Avg
-190.00%
Market Cap
$14.44M
Return on Equity (ROE)
-19.08%
TTM Avg
-28.50%
3Y Avg
-28.27%
5Y Avg
-100.79%
Market Cap
$16.53M
Return on Equity (ROE)
-170.55%
TTM Avg
-79.16%
3Y Avg
-71.01%
5Y Avg
-42.13%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | $15.54M | N/A | -257.58% | -197.65% | -111.06% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.65M | -348.81% | -160.92% | -184.71% | -151.29% |
| Jin Medical International Ltd. (ZJYL)vs › | $15.10M | 4.02% | 8.39% | 11.64% | 14.29% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.24M | -951.92% | -161.65% | -122.41% | -87.71% |
| BioCardia, Inc. (BCDA)vs › | $15.79M | -271.81% | -934.34% | -347.56% | -265.02% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.03M | -42.72% | -65.53% | -58.02% | -43.63% |
| Dyadic International, Inc. (DYAI)vs › | $16.50M | N/A | -416.37% | -259.03% | -190.00% |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.44M | -19.08% | -28.50% | -28.27% | -100.79% |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.53M | -170.55% | -79.16% | -71.01% | -42.13% |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.67M | -71.57% | -65.12% | -85.39% | -90.29% |
ROE
N/A
ROA
-201.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2020-12-31 | -388.31% |
| 2020-09-30 | -240.54% |
| 2020-06-30 | -145.90% |
| 2020-03-31 | -112.17% |
| 2019-12-31 | -400.99% |
| 2019-09-30 | -349.35% |
| 2019-06-30 | -261.76% |
| 2019-03-31 | -169.94% |
| 2018-12-31 | -97.40% |
| 2018-09-30 | -93.08% |
| 2018-06-30 | -66.42% |
| 2018-03-31 | -143.96% |
| 2017-12-31 | -99.63% |
| 2017-09-30 | -82.79% |
| 2017-06-30 | -66.98% |
| 2017-03-31 | -81.26% |
| 2016-12-31 | -67.54% |
| 2016-09-30 | -66.91% |
| 2016-06-30 | -75.95% |
| 2016-03-31 | -67.32% |
| 2015-12-31 | -59.58% |
| 2015-09-30 | -52.16% |
| 2015-06-30 | -42.22% |
| 2015-03-31 | -31.99% |
| 2014-12-31 | -36.64% |
| 2014-09-30 | -27.21% |
| 2014-06-30 | -39.18% |
| 2014-03-31 | -29.17% |
| 2013-12-31 | -21.91% |
| 2013-06-30 | -33.96% |
